

## **Rutgers Cancer Institute – Lymphoma Tumor Board**

**Provided by Rutgers Cancer Institute, Rutgers Robert Wood Johnson Medical School,  
Department of Radiology and Department of Pathology**

### ***Interesting Cases of the Week***

**Rutgers Cancer Institute, East Tower, 9<sup>th</sup> Floor, Room 916**

**Virtual: <https://rutgers.zoom.us/j/97256424770?pwd=SDRpaGk2SGVvRTMrSXJHSzk1b054QT09>**

**Monday, June 23, 2025 - 12:00-1:00pm**

**Presenters:** Matthew Matasar, MD; Joanna Rhodes, MD; Yun Kyoung (Claire) Tiger, MD, PhD

### **Learning Objectives**

At the conclusion of this activity, participants should be better able to:

- Analyze oncological decision-making processes and judgment to identify approaches to patient management and care.
- Evaluate oncology research developments that will continually improve the quality of care for cancer patients.
- Monitor and continually improve the quality of care to patients with cancer.
- Relate case findings to healthcare team members in order to improve the multidisciplinary approach in the management of patients with cancer.

### **Target Audience**

This activity is designed for medical oncologists, pharmacists, surgical oncologists, general surgeons, radiation oncologists, radiologists, hematologists, pathologists, physician assistants, nurses, and nurse practitioners.

### **Accreditation**



In support of improving patient care, Rutgers Biomedical and Health Sciences is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

**Physicians:** Rutgers Biomedical and Health Sciences designates this live activity for a maximum of 1 *AMA PRA Category 1 Credit™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Nurses:** This activity is awarded 1 ANCC contact hour.

**Pharmacists:** This knowledge-based activity qualifies for 1 contact hour of continuing pharmacy education credit.

### **Disclosure Declarations**

The following speakers have relevant financial relationships with ineligible companies: Matthew Matasar, MD; Consultant: ADC Therapeutics, Allogene, Arvinas, AstraZeneca, Bristol Myers Squibb, Genentech, Genmab, Johnson & Johnson, Regeneron Pharmaceuticals, Roche; Expert Witness: Bayer; Joanna Rhodes, MD; Consultant: AbbVie, ADC Therapeutics, AstraZeneca, Beigene, Genentech, Genmab, Janssen Pharmaceuticals, Lilly, LOXO Oncology, Pharmacyclics, Seagen; Grant/Research Support: AbbVie, Janssen

Pharmaceuticals, Lilly; Independent Contractor (including contracted research): Aptitude Health, Curio Science, MJH Life Sciences; Yun Kyoung (Claire) Tiger, MD, PhD has no relevant financial relationships with ineligible companies to disclose.

Speakers are required to disclose discussion of off-label/investigational uses of commercial products/devices in their presentation. These disclosures will be made to the audience at the time of the activity.

**Planning Committee:** The following planners have relevant financial relationships with ineligible companies: Matthew Matasar, MD; Consultant: ADC Therapeutics, Allogene, Arvinas, AstraZeneca, Bristol Myers Squibb, Genentech, Genmab, Johnson & Johnson, Regeneron Pharmaceuticals, Roche; Expert Witness: Bayer; Joanna Rhodes, MD: Consultant: AbbVie, ADC Therapeutics, AstraZeneca, Beigene, Genentech, Genmab, Janssen Pharmaceuticals, Lilly, LOXO Oncology, Pharmacyclics, Seagen; Grant/Research Support: AbbVie, Janssen Pharmaceuticals, Lilly; Independent Contractor (including contracted research): Aptitude Health, Curio Science, MJH Life Sciences. The following planners have no relevant financial relationships with ineligible companies to disclose: David Awad, PharmD, BCOPC, Kimberly Laino, MSN, FNP-BC, OCN, Tiger, Yun Kyoung (Claire) Tiger, MD. All of the relevant financial relationships listed have been mitigated.

Rutgers Health CE Staff: Patrick Dwyer and Elizabeth Ward have no relevant financial relationships with ineligible companies to disclose.